GRTS Gritstone bio Inc
Price (delayed)
$0.589
Market cap
$69.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.09
Enterprise value
$119.89M
Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first,
Highlights
The EPS is up by 13% year-on-year and by 12% since the previous quarter
The net income is up by 8% since the previous quarter
The equity has dropped by 80% year-on-year but it has surged by 59% since the previous quarter
GRTS's quick ratio has dropped by 55% year-on-year but it is up by 29% since the previous quarter
Gritstone bio's debt has increased by 7% YoY
Key stats
What are the main financial stats of GRTS
Market
Valuations
Earnings
Shares outstanding
118.11M
Market cap
$69.57M
Enterprise value
$119.89M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.88
Price to sales (P/S)
5.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.21
Revenue
$14.61M
EBIT
-$128.22M
EBITDA
-$107.08M
Free cash flow
-$112.43M
Per share
Balance sheet
Liquidity
EPS
-$1.09
Free cash flow per share
-$0.78
Book value per share
$0.2
Revenue per share
$0.1
TBVPS
$0.99
Total assets
$142.54M
Total liabilities
$120.35M
Debt
$102.49M
Equity
$22.19M
Working capital
$36.81M
Debt to equity
4.62
Current ratio
2.54
Quick ratio
2.38
Net debt/EBITDA
-0.47
Margins
Efficiency
Dividend
EBITDA margin
-732.9%
Gross margin
100%
Net margin
-910.5%
Operating margin
-934%
Return on assets
-82.5%
Return on equity
-328.5%
Return on invested capital
-67.6%
Return on capital employed
-108.1%
Return on sales
-877.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GRTS stock price
How has the Gritstone bio stock price performed over time
Intraday
5.14%
1 week
19.72%
1 month
17.78%
1 year
-58.23%
YTD
-71.13%
QTD
-4.68%
Financial performance
How have Gritstone bio's revenue and profit performed over time
Revenue
$14.61M
Gross profit
$14.61M
Operating income
-$136.47M
Net income
-$133.03M
Gross margin
100%
Net margin
-910.5%
The revenue has grown by 25% YoY but it has contracted by 7% from the previous quarter
GRTS's gross profit is up by 25% YoY but it is down by 7% QoQ
The company's operating margin rose by 18% YoY
Gritstone bio's net margin has increased by 18% YoY
Growth
What is Gritstone bio's growth rate over time
Valuation
What is Gritstone bio stock price valuation
P/E
N/A
P/B
2.88
P/S
5.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.21
The EPS is up by 13% year-on-year and by 12% since the previous quarter
The equity has dropped by 80% year-on-year but it has surged by 59% since the previous quarter
GRTS's P/B is 59% below its last 4 quarters average of 6.7 and 6% below its 5-year quarterly average of 2.9
The stock's price to sales (P/S) is 80% less than its 5-year quarterly average of 27.6 and 63% less than its last 4 quarters average of 14.8
The revenue has grown by 25% YoY but it has contracted by 7% from the previous quarter
Efficiency
How efficient is Gritstone bio business performance
The ROE has declined by 41% since the previous quarter
Gritstone bio's ROA has decreased by 39% YoY and by 3.1% from the previous quarter
The return on sales is up by 20% year-on-year and by 2.2% since the previous quarter
Dividends
What is GRTS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GRTS.
Financial health
How did Gritstone bio financials performed over time
The company's total assets is 18% higher than its total liabilities
GRTS's quick ratio has dropped by 55% year-on-year but it is up by 29% since the previous quarter
Gritstone bio's current ratio has plunged by 54% YoY but it has increased by 27% from the previous quarter
The equity has dropped by 80% year-on-year but it has surged by 59% since the previous quarter
Gritstone bio's debt to equity has decreased by 38% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.